Fondaparinux Market Size To Reach $990.9 Million By 2030

March 2025 | Report Format: Electronic (PDF)

Fondaparinux Market Growth & Trends

The global fondaparinux market size is estimated to reach USD 990.9 million by 2030, registering to grow at a CAGR of 6.3% from 2025 to 2030 according to a new report by Grand View Research, Inc. Fondaparinux is majorly used during knee and hip replacement surgeries. Arixtra, manufactured by GSK group of companies is the branded drug of Fondaparinux. The drug witnessed patent expiry in 2002. As the active molecule is highly complex to manufacture, it faced low generic competition until 2011. Generic manufacturer companies, such as Alchemia Ltd. and Apotex, Inc., received the Abbreviated New Drug Application approval in 2011 and instantly started the production of generic drugs.

Fondaparinux is used as an anticoagulant and shows improved survival compared with low-molecular-weight heparin. It is used for the prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and is administered subcutaneously. Moreover, Fondaparinux lowers the risk of ischemic events

The increasing collaboration between the key players for acquiring the Intellectual Property Rights (IPRs) in order to manufacture the molecule through patented technology is expected to drive growth. For instance, in July 2016 Dr. Reddy’s Laboratories Ltd. entered into an agreement with Alchemia Ltd. to purchase the IPRs of fondaparinux sodium for USD 17.5 million. In September 2014, Mylan N.V. purchased branded and generic versions of fondaparinux sodium from Aspen Global, Inc. for USD 225 million. The deal gave Mylan N.V. access to one of the two generics indicated for the treatment of PE.

key Request a free sample copy or view report summary: Fondaparinux Market Report

Fondaparinux Market Report Highlights

The generic segment accounted for the largest revenue share of 52.1% in 2024 and is expected to maintain its dominance during the forecast period.
The Deep Vein Thrombosis (DVT) segment accounted for a leading share of the market in 2024.
Hospital pharmacies emerged as the leading distribution channel for fondaparinux in 2024
North America fondaparinux market dominated the global market and accounted for the largest revenue share of 37.6% in 2024